A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 8, 2019

Primary Completion Date

December 26, 2019

Study Completion Date

December 26, 2019

Conditions
Healthy
Interventions
BIOLOGICAL

Imvanex

Imvanex 0.5 milliliter (mL) suspension for injection will be administered as single subcutaneous (SC) injection.

BIOLOGICAL

Shingrix

Shingrix 0.5 mL suspension will be administered as single intramuscular (IM) injection.

BIOLOGICAL

LPS

LPS 1.0 nanogram per kilogram (ng/kg) endotoxin suspension will be administered as single IV injection.

BIOLOGICAL

Candin

Candin 0.1 mL solution for injection will be administered as one intradermal injection.

OTHER

Skin Biopsy

3 punch biopsies will be performed and lower abdomen tissue biopsy specimens will be collected on Day 1.

OTHER

Saline Control

Saline control solution for injection will be administered as one intradermal injection.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03953196 - A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants | Biotech Hunter | Biotech Hunter